65,437 trials
Bowel; Disease, Carbohydrate Absorption · Difficulty Walking · Colorectal Neoplasms
Primary: Meters Walked During 2-Minute Walk Test — 70; 64 meters — p=0.75
Seasonal Allergic Rhinitis
Primary: Mean Nasal Symptom Score — 3.66; 4.69 score — p=<0.001
Healthy Volunteers
Primary: Maximum Plasma Concentration (Cmax) for Balovaptan — 31.5; 125; 140 ng/mL
Acute Respiratory Viral Infections · Influenza
Primary: Time to Sustained Improvement in Clinical Symptoms Based on Modified Jackson Scale for ARVI — 57.38; 67.75; 69.64 hours — p=0.3541
HIV Infections
Primary: CSF (Cerebrospinal Fluid) : Plasma Ratio of Maraviroc 1H Magnetic Resonance Spectroscopy (1H-MRS) — 1.01 ratio
Delirium
Primary: Number of Participants With Delirium — 41; 33 Participants
Non-valvular Atrial Fibrillation
Primary: Event Rate Per 100 Participant-Years For First Occurrence of Stroke and Systemic Embolism Events After Index Date — 3.2; 1.67; 2.08; 1.79 Events Per 100…
Alcohol Use Disorder · Alcohol Withdrawal
Primary: Percent of Subjects With no Heavy Drinking Days (PSNHDD) — 12; 4 Participants — p=.028
Bipolar Disorder
Primary: Mean Change in the Young Mania Rating Scale (YMRS) Score — -8.1 score on a scale
Dyslipidemias
Primary: Change From Baseline in Fridericia's Correction for QT Interval (QTcF) — -4.6; 11.5; -6.0; -6.1 msec
Type 2 Diabetes Mellitus
Primary: Change From Baseline in HbA1c at the End of Treatment Period I — -0.71; 0.01 Percent HbA1c — p=<0.0001
Hepatitis B, Chronic
Primary: Percentage of Participants With Serum Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <20 International Unit Per Milliliter (IU/mL) at Week 144 — 77.0 Percentage of…
Coronary Artery Disease, Hypercholesterolemia, Hypertension
Primary: Achievement Rate for Low Density Lipoprotein-Cholesterol (LDL-C) for Overall — 0.79; 0.67; 0.83; 0.57 Ratio
Stroke · Cerebrovascular Accident · Hemiparesis
Primary: Change in Fugl-Meyer Assessment of Sensorimotor Function From Baseline to Day 100 — 14.8; 12.8; 39.7; 37.8 units on a scale
Parkinson Disease
Primary: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] Related to aDBS — 0; 0; 0 Number of Treatment Emergent AEs